Spes Immunotherapeutics Joins Prestigious i4KIDS Acceleration Programme 2025

Barcelona, June 2025 – Spes Immunotherapeutics is proud to announce its selection for the esteemed i4KIDS Acceleration Programme 2025, an initiative focused on accelerating groundbreaking healthcare innovations specifically tailored for pediatric care.

This selection recognizes Spes Immunotherapeutics’ innovative approach to immunotherapy, designed to revolutionize pediatric oncology care. The company’s proprietary platform leverages advanced technologies to target unique cancer drivers, promising safer and more effective therapies for children suffering from acute leukemia.

The i4KIDS Programme, supported by the Innovation4Kids network, provides comprehensive resources including expert mentorship, strategic guidance, and access to leading healthcare institutions. Participation in this program will significantly advance Spes Immunotherapeutics' clinical and commercial milestones, moving groundbreaking treatments closer to market and directly impacting young patients’ lives.

"Joining i4KIDS marks a significant milestone for us," said Gioele Stoffel, Co-founder and Head of Business at Spes Immunotherapeutics. "The resources and expert support from this program will be instrumental in accelerating our mission to deliver life-changing therapies to pediatric patients."

Dr. Ricky Tirtakusuma, Co-founder and Head of R&D, added, "This recognition underscores the strength and potential of our technology platform. We look forward to collaborating with the program’s network of experts to refine our therapies and expedite their path to clinical application."

The program’s collaborative environment is set to further enhance Spes Immunotherapeutics’ strategic growth, scientific innovation, and commitment to transforming pediatric healthcare outcomes.

For more information about the i4KIDS Acceleration Programme 2025, please visit: https://www.innovation4kids.org/en/projects-i4kids-acceleration-programme-2025/